• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生物活性鞘脂作为冠状动脉疾病的主要调节因子

Bioactive Sphingolipids as Major Regulators of Coronary Artery Disease.

作者信息

Song Jae-Hwi, Kim Goon-Tae, Park Kyung-Ho, Park Woo-Jae, Park Tae-Sik

机构信息

Department of Life Science, Gachon University, Sungnam 13120, Republic of Korea.

Department of Nutrition, Hallym University, Chuncheon 24252, Republic of Korea.

出版信息

Biomol Ther (Seoul). 2021 Jul 1;29(4):373-383. doi: 10.4062/biomolther.2020.218.

DOI:10.4062/biomolther.2020.218
PMID:33903284
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8255146/
Abstract

Atherosclerosis is the deposition of plaque in the main arteries. It is an inflammatory condition involving the accumulation of macrophages and various lipids (low-density lipoprotein [LDL] cholesterol, ceramide, S1P). Moreover, endothelial cells, macrophages, leukocytes, and smooth muscle cells are the major players in the atherogenic process. Sphingolipids are now emerging as important regulators in various pathophysiological processes, including the atherogenic process. Various sphingolipids exist, such as the ceramides, ceramide-1-phosphate, sphingosine, sphinganine, sphingosine-1-phosphate (S1P), sphingomyelin, and hundreds of glycosphingolipids. Among these, ceramides, glycosphingolipids, and S1P play important roles in the atherogenic processes. The atherosclerotic plaque consists of higher amounts of ceramide, glycosphingolipids, and sphingomyelin. The inhibition of the de novo ceramide biosynthesis reduces the development of atherosclerosis. S1P regulates atherogenesis via binding to the S1P receptor (S1PR). Among the five S1PRs (S1PR1-5), S1PR1 and S1PR3 mainly exert anti-atherosclerotic properties. This review mainly focuses on the effects of ceramide and S1P via the S1PR in the development of atherosclerosis. Moreover, it discusses the recent findings and potential therapeutic implications in atherosclerosis.

摘要

动脉粥样硬化是指斑块在主要动脉中的沉积。它是一种炎症性疾病,涉及巨噬细胞和各种脂质(低密度脂蛋白[LDL]胆固醇、神经酰胺、1-磷酸鞘氨醇[S1P])的积累。此外,内皮细胞、巨噬细胞、白细胞和平滑肌细胞是动脉粥样硬化形成过程中的主要参与者。鞘脂现在正成为包括动脉粥样硬化形成过程在内的各种病理生理过程中的重要调节因子。存在多种鞘脂,如神经酰胺、1-磷酸神经酰胺、鞘氨醇、二氢鞘氨醇、1-磷酸鞘氨醇(S1P)、鞘磷脂和数百种糖鞘脂。其中,神经酰胺、糖鞘脂和S1P在动脉粥样硬化形成过程中起重要作用。动脉粥样硬化斑块含有较高含量的神经酰胺、糖鞘脂和鞘磷脂。抑制从头合成神经酰胺可减少动脉粥样硬化的发展。S1P通过与S1P受体(S1PR)结合来调节动脉粥样硬化的发生。在五种S1PR(S1PR1 - 5)中,S1PR1和S1PR3主要发挥抗动脉粥样硬化的特性。本综述主要关注神经酰胺和S1P通过S1PR在动脉粥样硬化发展过程中的作用。此外,还讨论了动脉粥样硬化方面的最新研究结果和潜在的治疗意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5eef/8255146/fc2879c640e5/bt-29-4-373-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5eef/8255146/fc2879c640e5/bt-29-4-373-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5eef/8255146/fc2879c640e5/bt-29-4-373-f1.jpg

相似文献

1
Bioactive Sphingolipids as Major Regulators of Coronary Artery Disease.生物活性鞘脂作为冠状动脉疾病的主要调节因子
Biomol Ther (Seoul). 2021 Jul 1;29(4):373-383. doi: 10.4062/biomolther.2020.218.
2
Sphingolipids and Atherosclerosis: The Dual Role of Ceramide and Sphingosine-1-Phosphate.鞘脂与动脉粥样硬化:神经酰胺和1-磷酸鞘氨醇的双重作用
Antioxidants (Basel). 2023 Jan 6;12(1):143. doi: 10.3390/antiox12010143.
3
Rewiring Endothelial Sphingolipid Metabolism to Favor S1P Over Ceramide Protects From Coronary Atherosclerosis.重塑内皮鞘脂代谢以促进 S1P 而非神经酰胺有利于保护冠状动脉粥样硬化。
Circ Res. 2024 Apr 12;134(8):990-1005. doi: 10.1161/CIRCRESAHA.123.323826. Epub 2024 Mar 8.
4
Sphingolipids in Atherosclerosis: Chimeras in Structure and Function.鞘脂类在动脉粥样硬化中的作用:结构与功能的嵌合体。
Int J Mol Sci. 2022 Oct 8;23(19):11948. doi: 10.3390/ijms231911948.
5
Sphingosine-1-phosphate promotes the proliferation and attenuates apoptosis of Endothelial progenitor cells via S1PR1/S1PR3/PI3K/Akt pathway.鞘氨醇-1-磷酸通过 S1PR1/S1PR3/PI3K/Akt 通路促进内皮祖细胞的增殖并抑制其凋亡。
Cell Biol Int. 2018 Nov;42(11):1492-1502. doi: 10.1002/cbin.10991. Epub 2018 Jul 8.
6
Impact of Sphingolipid Mediators on the Determination of Cochlear Survival in Ototoxicity.鞘脂介质对耳毒性中耳蜗存活判定的影响
Curr Mol Pharmacol. 2018;11(4):279-284. doi: 10.2174/1874467211666180516101111.
7
Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage.冠状病毒病时代肺部病理学中的鞘脂:鞘脂参与肺损伤发病机制的综述
Front Physiol. 2021 Oct 8;12:760638. doi: 10.3389/fphys.2021.760638. eCollection 2021.
8
Feeding Stimulates Sphingosine-1-Phosphate Mobilization in Mouse Hypothalamus.进食刺激小鼠下丘脑中的鞘氨醇-1-磷酸的动员。
Int J Mol Sci. 2019 Aug 17;20(16):4008. doi: 10.3390/ijms20164008.
9
Elevating Endogenous Sphingosine-1-Phosphate (S1P) Levels Improves Endothelial Function and Ameliorates Atherosclerosis in Low Density Lipoprotein Receptor-Deficient (LDL-R-/-) Mice.升高内源性鞘氨醇-1-磷酸(S1P)水平可改善低密度脂蛋白受体缺陷(LDL-R-/-)小鼠的内皮功能并减轻动脉粥样硬化。
Thromb Haemost. 2018 Aug;118(8):1470-1480. doi: 10.1055/s-0038-1666870. Epub 2018 Jul 30.
10
Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis.鞘氨醇-1-磷酸磷酸水解酶在鞘脂代谢和细胞凋亡调控中的作用
J Cell Biol. 2002 Sep 16;158(6):1039-49. doi: 10.1083/jcb.200203123.

引用本文的文献

1
Sphingolipid metabolites involved in the pathogenesis of atherosclerosis: perspectives on sphingolipids in atherosclerosis.参与动脉粥样硬化发病机制的鞘脂代谢产物:动脉粥样硬化中鞘脂的研究视角
Cell Mol Biol Lett. 2025 Feb 7;30(1):18. doi: 10.1186/s11658-024-00679-2.
2
Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans-fat-induced atherosclerosis.鞘脂生物合成通量的改变和脂蛋白转运导致反式脂肪诱导的动脉粥样硬化。
Cell Metab. 2025 Jan 7;37(1):274-290.e9. doi: 10.1016/j.cmet.2024.10.016. Epub 2024 Nov 14.
3
Sphingomyelins of Local Fat Depots and Blood Serum as Promising Biomarkers of Cardiovascular Diseases.

本文引用的文献

1
Targeting a ceramide double bond improves insulin resistance and hepatic steatosis.靶向神经酰胺双键可改善胰岛素抵抗和肝脂肪变性。
Science. 2019 Jul 26;365(6451):386-392. doi: 10.1126/science.aav3722. Epub 2019 Jul 4.
2
CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity.CerS6 衍生的神经酰胺与 Mff 相互作用,促进肥胖中的线粒体碎片化。
Cell. 2019 May 30;177(6):1536-1552.e23. doi: 10.1016/j.cell.2019.05.008.
3
Sphingosine-1-phosphate (S1P) induces potent anti-inflammatory effects in vitro and in vivo by S1P receptor 4-mediated suppression of 5-lipoxygenase activity.
局部脂肪组织和血清中的神经鞘磷脂作为心血管疾病有前途的生物标志物。
Sovrem Tekhnologii Med. 2024;16(1):54-64. doi: 10.17691/stm2024.16.1.06. Epub 2024 Feb 28.
4
Coronary Event Risk Test (CERT) as a Risk Predictor for the 10-Year Clinical Outcome of Patients with Peripheral Artery Disease.冠状动脉事件风险测试(CERT)作为外周动脉疾病患者10年临床结局的风险预测指标。
J Clin Med. 2023 Sep 23;12(19):6151. doi: 10.3390/jcm12196151.
5
Lipid Biomarkers and Atherosclerosis-Old and New in Cardiovascular Risk in Childhood.脂类生物标志物与动脉粥样硬化——儿童心血管风险的新老问题。
Int J Mol Sci. 2023 Jan 23;24(3):2237. doi: 10.3390/ijms24032237.
6
Presence of Ceramidase Activity in Electronegative LDL.电负性 LDL 中 Ceramidase 活性的存在。
Int J Mol Sci. 2022 Dec 22;24(1):165. doi: 10.3390/ijms24010165.
7
Circulating Biomarkers for Laboratory Diagnostics of Atherosclerosis-Literature Review.用于动脉粥样硬化实验室诊断的循环生物标志物——文献综述
Diagnostics (Basel). 2022 Dec 13;12(12):3141. doi: 10.3390/diagnostics12123141.
8
Plasma Ceramide Levels Are Elevated in Patients With Early Coronary Atherosclerosis and Endothelial Dysfunction.血浆神经酰胺水平在伴有早期冠状动脉粥样硬化和内皮功能障碍的患者中升高。
J Am Heart Assoc. 2022 Apr 5;11(7):e022852. doi: 10.1161/JAHA.121.022852. Epub 2022 Mar 18.
9
The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism.鞘氨醇 1-磷酸受体 2/4 拮抗剂 JTE-013 会对鞘脂代谢产生非靶点作用。
Sci Rep. 2022 Jan 10;12(1):454. doi: 10.1038/s41598-021-04009-w.
10
Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets.神经酰胺在非酒精性脂肪性肝病(NAFLD)动脉粥样硬化(ATS)发展中的作用:机制与治疗靶点
Diagnostics (Basel). 2021 Nov 5;11(11):2053. doi: 10.3390/diagnostics11112053.
鞘氨醇-1-磷酸(S1P)通过 S1P 受体 4 介导的 5-脂氧合酶活性抑制,在体外和体内产生强大的抗炎作用。
FASEB J. 2019 Feb;33(2):1711-1726. doi: 10.1096/fj.201800221R. Epub 2018 Sep 6.
4
Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study.血浆神经酰胺与内脏肥胖、胰岛素抵抗及 2 型糖尿病发生的关系:达拉斯心脏研究。
Diabetologia. 2018 Dec;61(12):2570-2579. doi: 10.1007/s00125-018-4720-1. Epub 2018 Aug 29.
5
The effect of high-fat diet and inhibition of ceramide production on insulin action in liver.高脂肪饮食和神经酰胺生成抑制对肝脏胰岛素作用的影响。
J Cell Physiol. 2019 Feb;234(2):1851-1861. doi: 10.1002/jcp.27058. Epub 2018 Aug 1.
6
Plasma Ceramides.血浆神经酰胺。
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1933-1939. doi: 10.1161/ATVBAHA.118.311199.
7
nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe Mice.nSMase2(中性鞘磷脂酶 2 型)缺乏或 GW4869 抑制可减少载脂蛋白 E 小鼠的炎症和动脉粥样硬化。
Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1479-1492. doi: 10.1161/ATVBAHA.118.311208. Epub 2018 May 24.
8
Ceramide Remodeling and Risk of Cardiovascular Events and Mortality.神经酰胺重塑与心血管事件和死亡风险。
J Am Heart Assoc. 2018 May 3;7(10):e007931. doi: 10.1161/JAHA.117.007931.
9
Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study.循环神经酰胺、胰岛素、HOMA-IR 和 HOMA-B:强心家族研究。
Diabetes. 2018 Aug;67(8):1663-1672. doi: 10.2337/db17-1449. Epub 2018 Mar 27.
10
Could Ceramides Become the New Cholesterol?神经酰胺会成为新的胆固醇吗?
Cell Metab. 2018 Feb 6;27(2):276-280. doi: 10.1016/j.cmet.2017.12.003. Epub 2018 Jan 4.